BacteremiaNCT06605677
Knowledge Attitude and Practice Regarding Bloodstream Bacterial Infections and Antibiotics Usage Among Doctors.
An observational study of Bacteremia and Antimicrobial Stewardship, run by Abu Dhabi Health Services Company at 1 site in United Arab Emirates.
Trial summary
This study is designed to use a questionnaire to assess doctors' knowledge, attitudes, and practices regarding bloodstream bacterial infections and antibiotic use in Tawam and Al Ain tertiary Hospitals (both hospitals have the same medical team) in Al Ain City, UAE. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Bacteremia, Antimicrobial Stewardship, Antibiotic Use
- What is being tested?
- Questionnaire
- How many people
- 100 participants
- Where
- 1 siteUnited Arab Emirates
- Study dates
- 9 Sep 2024to 9 Mar 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: Licensed, practicing physicians, multinational
Who may be able to join
- All physicians with valid medical licenses working in Tawam and Al Ain tertiary hospitals
Who cannot join
- Infectious diseases physicians and Microbiologists
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Knowledge Attitude and Practice Regarding Bloodstream Bacterial Infections and Antibiotics Usage Among Doctors in a Tertiary Hospital in Al Ain City, UAE: A Cross-Sectional Descriptive Study.
This study is designed to use a questionnaire to assess doctors' knowledge, attitudes, and practices regarding bloodstream bacterial infections and antibiotic use in Tawam and Al Ain tertiary Hospitals (both hospitals have the same medical team) in Al Ain City, UAE.
Read the detailed description
Background: Bloodstream bacterial infection is a serious medical problem and one of the leading causes of death worldwide among all age groups. Appropriate and early antibiotic use has been associated with better outcomes based on many clinical trials. On the other hand, misuse and abuse of antibiotics have been linked to long hospital stays, significant morbidity and mortality, increased medical costs and rising antimicrobial resistance (AMR). Statistics in hospitals involved in the study, showed increased antibiotic consumption compared to previous years and other regional healthcare facilities. Rates of AMR in the UAE have increased significantly in the last decade, based on the 2022 annual report.
Aims and objectives This study will assess knowledge, attitude and practice regarding bloodstream bacterial infections and antibiotics use among doctors. It is a questionnaire-based cross-sectional descriptive study that will be conducted at Tawam and Al Ain Hospitals (tertiary hospital, both hospitals have the same medical team).
The investigators want to explore the degree of knowledge and attitude, assess the appropriate usage of antibiotics among doctors in different subspecialties, assess any possible barriers, and find solutions such as medical education for this challenging medical problem.
- Being tested
- Questionnaire
- Keywords
- bacteremia, antimicrobial resistance, antimicrobial stewardship, healthcare workers, antibiotic use, antibiotic abuse
- Medical subject headings
- Bacteremia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QuestionnaireOther
An online questionnaire will be sent through e-mail to participants. It is divided into 4 sections: demography and general information 9 questions, knowledge 10 questions, attitude 10 questions and practice 10 questions. No previous similar studies were conducted in the United Arab Emirates (UAE) or internationally based on a search in PubMed and Cochrane library. Hence a validated questionnaire is lacking. Therefore, the questionnaire for this study is designed based on questions encountered daily by colleagues during the consultation, and it can serve the purpose of this study. Consent will be obtained and signed electronically by participants before starting the questionnaire. Participation involves minimal risk. Responses will be anonymous and confidential. Participants' involvement is voluntary, and they can withdraw at any time without any consequences. The time to complete the questionnaire is around 10-15 minutes. Each response will be saved using a unique identifier number.
| Study group | Role | What they receive |
|---|---|---|
| All doctors with valid medical license in Tawam and Al Ain Hospitals | The group excludes infectious disease physicians and microbiologists. Receives: Other: Questionnaire |
What is being measured
The primary outcome is the main question the study is designed to answer.
Understanding physician knowledge on antibiotic use in bacterial bloodstream infections (bacteremia).
Questions to assess physicians' knowledge related to basic microbiology, bacterial infections and antibiotic spectrum of activity using dichotomous questions; yes/no.
Measured: 1 year
Understanding physician attitude on antibiotic use in bacterial bloodstream infections (bacteremia).
Questions to assess physicians' attitude in bacteremia management using dichotomous questions; yes/no, Likert scale or multiple choices.
Measured: 1 year
Understanding physician practices on antibiotic use in bacterial bloodstream infections (bacteremia).
Questions to assess physicians' practice in bacteremia management using dichotomous questions; yes/no, or multiple choices.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Sep 2024
- Study start9 Sep 2024
- Primary completion9 Mar 2025 (estimated)
- Study completion9 Mar 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for BacteremiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Abu Dhabi Health Services Company
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Noura Saif Alnuaimi, Abu Dhabi Health Services Company
- Investigators
- Noura Saif Alnuaimi, MD, Principal investigator, Abu Dhabi Health Services Co-SEHAAhmed Al Hammadi, MD, Study chair, Abu Dhabi Health Services Co-SEHA
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06605677
- Sponsor's protocol ID
- HREC SEHA-IRB-559
- Status last verified
- Sep 2024
- First submitted
- 18 Sep 2024
- Last updated
- 26 Sep 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Thomsen J et al. United Arab Emirates Surveillance of Antimicrobial Resistance Annual Report 2022.
Labelle A, Juang P, Reichley R, Micek S, Hoffmann J, Hoban A, Hampton N, Kollef M. The determinants of hospital mortality among patients with septic shock receiving appropriate initial antibiotic treatment*. Crit Care Med. 2012 Jul;40(7):2016-21. doi: 10.1097/CCM.0b013e318250aa72.
PubMed 22584765Zahar JR, Timsit JF, Garrouste-Orgeas M, Francais A, Vesin A, Descorps-Declere A, Dubois Y, Souweine B, Haouache H, Goldgran-Toledano D, Allaouchiche B, Azoulay E, Adrie C. Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality. Crit Care Med. 2011 Aug;39(8):1886-95. doi: 10.1097/CCM.0b013e31821b827c.
PubMed 21516036Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med. 1980 Mar;68(3):344-55. doi: 10.1016/0002-9343(80)90102-3.
PubMed 6987871Bearman GM, Wenzel RP. Bacteremias: a leading cause of death. Arch Med Res. 2005 Nov-Dec;36(6):646-59. doi: 10.1016/j.arcmed.2005.02.005.
PubMed 16216646
Study at a glance
From the registry record, last updated by the sponsor on 26 Sep 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Knowledge Attitude and Practice Regarding Bloodstream Bacterial Infections and Antibiotics Usage Among Doctors in a Tertiary Hospital in Al Ain City, UAE: A Cross-Sectional Descriptive Study.
- ClinicalTrials.gov ID
- NCT06605677
- Acronym / sponsor ID
- HREC SEHA-IRB-559
- Keywords
- bacteremia, antimicrobial resistance, antimicrobial stewardship, healthcare workers, antibiotic use, antibiotic abuse
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Abu Dhabi Health Services CompanyOther government
- Study start
- 9 Sep 2024 (actual)
- Primary completion
- 9 Mar 2025 (estimated)
- Study completion
- 9 Mar 2025 (estimated)
- First posted
- 20 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is designed to use a questionnaire to assess doctors' knowledge, attitudes, and practices regarding bloodstream bacterial infections and antibiotic use in Tawam and Al Ain tertiary Hospitals (both hospitals have the same medical team) in Al Ain City, UAE.
Detailed description
Background: Bloodstream bacterial infection is a serious medical problem and one of the leading causes of death worldwide among all age groups. Appropriate and early antibiotic use has been associated with better outcomes based on many clinical trials. On the other hand, misuse and abuse of antibiotics have been linked to long hospital stays, significant morbidity and mortality, increased medical costs and rising antimicrobial resistance (AMR). Statistics in hospitals involved in the study, showed increased antibiotic consumption compared to previous years and other regional healthcare facilities. Rates of AMR in the UAE have increased significantly in the last decade, based on the 2022 annual report.
Aims and objectives This study will assess knowledge, attitude and practice regarding bloodstream bacterial infections and antibiotics use among doctors. It is a questionnaire-based cross-sectional descriptive study that will be conducted at Tawam and Al Ain Hospitals (tertiary hospital, both hospitals have the same medical team).
The investigators want to explore the degree of knowledge and attitude, assess the appropriate usage of antibiotics among doctors in different subspecialties, assess any possible barriers, and find solutions such as medical education for this challenging medical problem.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| All doctors with valid medical license in Tawam and Al Ain Hospitals | – | Other: QuestionnaireThe group excludes infectious disease physicians and microbiologists. |
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- Licensed, practicing physicians, multinational
Key inclusion criteria (1 listed)
- All physicians with valid medical licenses working in Tawam and Al Ain tertiary hospitals
Key exclusion criteria (1 listed)
- Infectious diseases physicians and Microbiologists
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| QuestionnaireAn online questionnaire will be sent through e-mail to participants. It is divided into 4 sections: demography and general information 9 questions, knowledge 10 questions, attitude 10 questions and practice 10 questions. No previous similar studies were conducted in the United Arab Emirates (UAE) or internationally based on a search in PubMed and Cochrane library. Hence a validated questionnaire is lacking. Therefore, the questionnaire for this study is designed based on questions encountered daily by colleagues during the consultation, and it can serve the purpose of this study. Consent will be obtained and signed electronically by participants before starting the questionnaire. Participation involves minimal risk. Responses will be anonymous and confidential. Participants' involvement is voluntary, and they can withdraw at any time without any consequences. The time to complete the questionnaire is around 10-15 minutes. Each response will be saved using a unique identifier number. | Other | All doctors with valid medical license in Tawam and Al Ain Hospitals |
Primary outcome
Understanding physician knowledge on antibiotic use in bacterial bloodstream infections (bacteremia).
Time frame: 1 year
Questions to assess physicians' knowledge related to basic microbiology, bacterial infections and antibiotic spectrum of activity using dichotomous questions; yes/no.
Understanding physician attitude on antibiotic use in bacterial bloodstream infections (bacteremia).
Time frame: 1 year
Questions to assess physicians' attitude in bacteremia management using dichotomous questions; yes/no, Likert scale or multiple choices.
Understanding physician practices on antibiotic use in bacterial bloodstream infections (bacteremia).
Time frame: 1 year
Questions to assess physicians' practice in bacteremia management using dichotomous questions; yes/no, or multiple choices.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Sep 2024.
- Results publicationThomsen J et al. United Arab Emirates Surveillance of Antimicrobial Resistance Annual Report 2022.
- Results publication: PubMed 22584765Labelle A, Juang P, Reichley R, Micek S, Hoffmann J, Hoban A, Hampton N, Kollef M. The determinants of hospital mortality among patients with septic shock receiving appropriate initial antibiotic treatment*. Crit Care Med. 2012 Jul;40(7):2016-21. doi: 10.1097/CCM.0b013e318250aa72.
- Results publication: PubMed 21516036Zahar JR, Timsit JF, Garrouste-Orgeas M, Francais A, Vesin A, Descorps-Declere A, Dubois Y, Souweine B, Haouache H, Goldgran-Toledano D, Allaouchiche B, Azoulay E, Adrie C. Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality. Crit Care Med. 2011 Aug;39(8):1886-95. doi: 10.1097/CCM.0b013e31821b827c.
- Results publication: PubMed 6987871Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med. 1980 Mar;68(3):344-55. doi: 10.1016/0002-9343(80)90102-3.
- Results publication: PubMed 16216646Bearman GM, Wenzel RP. Bacteremias: a leading cause of death. Arch Med Res. 2005 Nov-Dec;36(6):646-59. doi: 10.1016/j.arcmed.2005.02.005.
- Individual participant dataSharing planned: No
Related trials for Bacteremia
RecruitingObservational study
Study of the Nasal Intracellular Reservoir of Staphylococcus Aureus in Patients With S. Aureus Bacteremia
Bacteria Infection Mechanism
Not yet recruitingPhase 4
Oral Switch in Bloodstream Infections in Immunocompromised Children
Bloodstream Infection, Bloodstream Infection Due to Central Venous Catheter
Not yet recruiting
Evaluation of an AI-Assisted Tool for CLABSI Surveillance at VA Medical Centers
Central Line-Associated Bloodstream Infection (CLABSI), Bacteremia
RecruitingPhase 2
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia
RecruitingObservational study
Middle East Study of Infections in Patients With Hematological Malignancies
Hematological Malignancy, Hematopoetic Stem Cell Transplantation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Noura Saif Alnuaimi, MD principal investigator
Abu Dhabi Health Services Co-SEHA
Ahmed Al Hammadi, MD study chair
Abu Dhabi Health Services Co-SEHA
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Bacteremia and Antimicrobial Stewardship, run by Abu Dhabi Health Services Company at 1 site in United Arab Emirates.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 26 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Arab Emirates. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Understanding physician knowledge on antibiotic use in bacterial bloodstream infections (bacteremia). (time frame: 1 year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06605677, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Sep 2024.